Drugs / OriC321
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05325801 | Apr 2022 → Mar 2024 | plasma cell myeloma | Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OriC321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05325801 ↗ |
| Modality | Cell therapy | “BMCA and GPRC5D dual target CAR-T cells(OriC321)” NCT05325801 ↗ |
| Target | GPRC5D | “BMCA and GPRC5D dual target CAR-T cells(OriC321)” NCT05325801 ↗ |